Seeking Alpha

lizard49's  Instablog

Send Message
I run a medical information website. Thirteen years and counting!
View lizard49's Instablogs on:
  • Four interesting stocks under $1
    Would you like some shares in a company that makes flying cars? How about medical marijuana? Today we'll take a quick look at four extremely interesting stocks trading at well under $1 per share.

    I have three criteria that even an extremely low-priced stock must meet before I'll even consider a buy. I normally invest only in healthcare stocks, since my background is in medicine.

    1. The company must have been in existence five years or more.
    2. There must be an actual product being made.
    3. Recent stock prices must be on an upward trend, no matter how tiny the increases.

    These four, out of many, have caught my attention today:

    StockIndustryClose 06/20/11
    52-week rangeMarket cap

    Alseres Pharmaceuticals, Inc. (OTCPK:ALSE) was founded in 1992 and focuses on drugs that act on the central nervous system. Its flagship product is Altropane, an imaging agent used in diagnosing Parkinson's disease and dementia. Alseres is listed as a sponsor for four clinical trials at

    Bioheart, Inc. (OTCPK:BHRT) was started in 1999 and is focused on the development of effective cell technologies to treat cardiovascular diseases. Bioheart is listed as a sponsor on four clinical trials of its MyoCell and MyoCath products.

    Cannabis Science, Inc. (OTCPK:CBIS) was formerly known as Cannex Therapeutics and Gulf Onshore, Inc. Its CEO is Steve Kubby, an activist and cancer patient who played a key role in the drafting and passage of California Proposition 215, and who has allegedly survived because of medical marijuana.

    Moller International (OTCPK:MLER) is the only non-healthcare stock on this short list. Moller has been in the process of building the M400X Skycar for many years. The stock has been offered to the public since at least 1997. Moller has scheduled a demonstration flight of the Skycar for invited members of the press on October 11, 2011.

    Disclosure: Long MLER.

    Jun 20 8:06 PM | Link | Comment!
  • Healthcare's supporting players: Medical transcription companies
    Medical transcription these days is a fast-paced, knowledge-intensive, high-tech, global business. I discuss three of the biggest players in the medical documentation arena below. Judging by EPS, recent stock price, RPE, and volume, only one of the three would be a reasonable buy at this time.  None of these companies pay dividends.

    Medical records in the United States are subject to strict privacy rules under HIPAA, the Health Insurance Portability and Accountability Act of 1996. These records are not intended to be used for treatment planning. They are produced quickly and are only intended to document the patient's treatment for purposes of insurance reimbursement, billing, and recordkeeping. Medical records are transcribed all over the world by employees and subcontractors of hospitals and transcription agencies, and increasingly by speech recognition software.

    MedQuist, Inc. (MEDQ.PK) produces more than 1.5 billion lines of transcription annually. Transcriptionists are usually paid by the line. MedQuist provides medical record transcription services under contract to hospitals, clinics, and physician practices. MedQuist has been on a buying spree for decades, snapping up transcription agencies from small mom-and-pop shops to larger, better-known entities such as Lernout & Hauspie in 2001. MedQuist completed the purchase of Spheris Transcription, with its more than 5,000 employees worldwide, in April 2010. Spheris had purchased HealthScribe in 2004, gaining more than 1,800 transcriptionists at that time.

    On September 28, 2010, MEDQ was trading at $4.96. In the past five years its stock has rarely traded above $12.50, closing at $12.25 on June 8, 2011, down 35 cents. But MedQuist's RPE, or revenue per employee, is only $62K. And on March 24, 2011, MedQuist voluntarily delisted its common stock from NASDAQ.

    Nuance Communications, Inc. (NASDAQ:NUAN), with EPS of 0.0071 to MedQuist's 0.96, fared better in the market on June 8, closing at $20.36, up 15 cents, on above-average volume. Nuance's website claims $100 million annual investment in R&D and 3 billion lines of transcription generated. According to, Nuance's RPE is an astonishing $197,665. Since May, CEO Paul Ricci has sold nearly 200,000 of his shares at $21.50 to $22, fueling the rumor that Apple (NASDAQ:AAPL) is interested in a takeover.

    Nuance offers a wide range of speech recognition systems, including eScription and Dragon Medical, to its healthcare clients. As an aside, I read on an internet message board that Nuance has recently lowered the line rate it pays its transcriptionists -- a shortsighted move if true, considering Nuance's extremely high RPE.

    Transcend Services (TRCR) made Rex Moore's Foolish 8 Stocks List at on June 7. Its quarterly EPS estimate is 0.32. However, Transcend's RPE is even lower than MedQuist's at just $52K. Transcend closed at $24.99 on June 8, down from $25.05. The day's volume was nearly twice the average amount.

    Medical transcription companies
    Stock Close 06/08/11
    Change 52-week range RPE EPS
    MEDQ.PK 12.25 -0.25 7.00-14.00 $62K 0.96
    NUAN 20.36 +0.15 14.45-22.93 $197K 0.0071
    TRCR 24.99 -0.06 12.01-27.09 $52K 0.32

    Low RPE numbers severely limit the potential for a company to become a global market leader, especially in a 24/7 service business which must compete with cheaper labor overseas.

    My opinion? That only one of these stocks is worth considering. That stock is NUAN, although I would completely lose interest in it if Apple doesn't pursue a takeover. Without the Apple factor, NUAN's low EPS would be a deal-breaker for me.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jun 09 1:05 PM | Link | Comment!
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.